{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:29:58Z","timestamp":1793431798167,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1046","license":[{"start":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Scleritis is a serious inflammatory condition that is often painful, and in severe cases can result in permanent loss of vision. Approximately half the patients affected have no identifiable cause, but 30%\u201340% have an underlying systemic autoimmune condition. Scleritis may be the initial manifestation of Wegener's granulomatosis or rheumatoid arthritis, and all patients with scleritis require a thorough systemic evaluation.<\/jats:p>\n               <jats:p>Scleritis has a variable presentation and disease course, and may be an acute monophasic illness, a relapsing remitting process, or take a chronic course. Treatment options include local therapy with subconjunctival steroid injections for non-necrotising scleritis, and systemic anti-inflammatory or immunosuppressive therapy. Biologic agents have been used with success in some refractory cases. Ocular and systemic morbidity is reduced by timely treatment with immunosuppressant medications.<\/jats:p>","DOI":"10.1136\/postgradmedj-2011-130282","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T04:12:34Z","timestamp":1347509554000},"page":"713-718","source":"Crossref","is-referenced-by-count":39,"title":["Scleritis: presentations, disease associations and management"],"prefix":"10.1093","volume":"88","author":[{"given":"Joanne","family":"Sims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"key":"2023041907171113400_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Brit J Ophthal"},{"key":"2023041907171113400_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0161-6420(94)31325-X","article-title":"Severity of scleritis and episcleritis","volume":"101","author":"","year":"1994","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(91)32269-3","article-title":"Progression of scleral disease","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthal"},{"key":"2023041907171113400_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2007.09.024","article-title":"Immunological markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis","volume":"145","author":"Lin","year":"2008","journal-title":"Am J Ophthal"},{"key":"2023041907171113400_bib6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0161-6420(94)31178-X","article-title":"Scleritis associated with rheumatoid arthritis and other systemic immune-mediated diseases","volume":"101","author":"Sainz de la Maza","year":"1994","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0161-6420(95)30970-0","article-title":"Scleritis associated with systemic vasculitic disorders","volume":"102","author":"Sainz de la Maza","year":"1995","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archopht.120.1.15","article-title":"Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy","volume":"120","author":"Sainz de la Maza","year":"2002","journal-title":"Arch Ophthal"},{"key":"2023041907171113400_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ajo.2009.06.025","article-title":"Chronic herpes simplex scleritis: characterisation of 9 cases of an underrecognised clinical entity","volume":"148","author":"Bhat","year":"2009","journal-title":"Am J Ophthal"},{"key":"2023041907171113400_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bjo.76.1.17","article-title":"Surgically induced necrotising sclerokeratitis (SINS)\u2014precipitating factors and response to treatment","volume":"76","author":"O'Donoghue","year":"1992","journal-title":"Br J Ophthal"},{"key":"2023041907171113400_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1076\/soph.17.3.124.14786","article-title":"Sterile corneal melting and necrotising scleritis after cataract surgery in patients with rheumatoid arthritis and collagen vascular disease","volume":"17","author":"Perez","year":"2002","journal-title":"Semin Ophthal"},{"key":"2023041907171113400_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ophtha.2003.12.052","article-title":"Adverse ocular drug reactions recently identified by the National Registry of Drug-induced ocular side effects","volume":"111","author":"Fraunfelder","year":"2004","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/09273940591004133","article-title":"Masquerade scleritis","volume":"1","author":"Kafkala","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"2023041907171113400_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthal"},{"key":"2023041907171113400_bib15","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/S0161-6420(99)90543-2","article-title":"Posterior scleritis: clinical features, systemic associations and outcome in a large series of patients","volume":"106","author":"McCluskey","year":"1999","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Scleritis","volume":"50","author":"Okhravi","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"2023041907171113400_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bjo.2009.164962","article-title":"Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis","volume":"94","author":"Roufas","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"2023041907171113400_bib18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ophtha.2005.05.008","article-title":"Evaluation of subconjunctival triamcinolone for nonnecrotising anterior scleritis","volume":"112","author":"Albini","year":"2005","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0161-6420(01)01018-1","article-title":"A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis","volume":"109","author":"Zamir","year":"2002","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0161-6420(95)30963-3","article-title":"Therapy of nonnecrotising anterior scleritis with subconjunctival corticosteroid injection","volume":"102","author":"Tu","year":"1995","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/bjo.60.3.227","article-title":"Evaluation or eyes enucleated for scleritis","volume":"60","author":"Fraunfelder","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"2023041907171113400_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","article-title":"Mortality rate in rheumatoid arthritis patients developing necrotising scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression","volume":"91","author":"Foster","year":"1984","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2003.013961","article-title":"Infliximab in active early rheumatoid arthritis","volume":"64","author":"Breedveld","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023041907171113400_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumour necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Care Res"},{"key":"2023041907171113400_bib25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor \u03b1 blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"2023041907171113400_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J opthalmol"},{"key":"2023041907171113400_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09273941003739928","article-title":"Rituximab treatment for persistent scleritis associated with rheumatoid arthritis","volume":"18","author":"Iaccheri","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"2023041907171113400_bib29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/bjo.2008.147157","article-title":"Rituximab for treatment of scleritis associated with rheumatoid arthritis","volume":"93","author":"Chauhan","year":"2009","journal-title":"Br J Ophthal"},{"key":"2023041907171113400_bib30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br J Ophthal"},{"key":"2023041907171113400_bib31","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective for the treatment of refractory Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023041907171113400_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00003226-200003000-00002","article-title":"Lamellar corneal patch grafts in the management of corneal melting","volume":"19","author":"Soong","year":"2000","journal-title":"Cornea"},{"key":"2023041907171113400_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.126.5.651","article-title":"Antineutrophil cytoplasmic antibody-associated active scleritis","volume":"126","author":"Hoang","year":"2008","journal-title":"Arch Ophthal"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/88\/1046\/713\/50018865\/postgradmedj-88-713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/88\/1046\/713\/50018865\/postgradmedj-88-713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:30:53Z","timestamp":1681889453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/88\/1046\/713\/6986784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":33,"journal-issue":{"issue":"1046","published-online":{"date-parts":[[2012,9,12]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2011-130282","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12]]},"published":{"date-parts":[[2012,9,12]]}}}